Demant A/S

Equities

DEMANT

DK0060738599

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:37 2024-05-15 am EDT			5-day change	1st Jan Change
325.8 ^DKK	+0.80%		+1.69%	+10.07%

May. 06	DEMANT : Q1 sales miss; organic growth guidance unchanged
May. 06	Transcript : Demant A/S, Q1 2024 Interim Management Statement Call, May 06, 2024

Demant A/S: New Head of Investor Relations

January 03, 2024 at 07:35 am EST

3.1.2024 13:34:42 CET | Demant A/S | Investor News

Investor news 3 January 2024

New Head of Investor Relations

As Demant’s current Head of Investor Relations, Mathias Holten Møller, will be taking on a new role internally at Demant, Peter Pudselykke has been promoted to new Head of Investor Relations effective 1 March 2024. Peter Pudselykke has been part of Demant’s Investor Relations team since December 2021, and prior to joining the Group, he worked as a portfolio manager with a large Danish institutional investor.

Effective 1 March 2024, Mathias Holten Møller will take on new responsibilities as Vice President of Business Finance for the Hearing Care business area. Until then, Mathias Holten Møller will continue to head up Demant’s Investor Relations activities and help ensure a smooth transition of responsibilities.

Going forward, the Investor Relations team will consist of Peter Pudselykke, Charles William Sumner and an additional team member to be recruited.

Further information:

Søren Nielsen, President & CEO

Phone +45 3917 7300

www.demant.com

Other contacts:

René Schneider, CFO

Mathias Holten Møller, Head of Investor Relations

Peter Pudselykke, Investor Relations Officer

Trine Kromann-Mikkelsen, VP Corporate Communication & Sustainability

Contacts

Henrik Axel Lynge Buchter, External Communication Manager, Corporate Communication & Sustainability, +45 2264 9982, heey@demant.com

About Demant A/S

Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.

Attachments

Investor News - New Head of Investor Relations.pdf

Latest news about Demant A/S

DEMANT : Q1 sales miss; organic growth guidance unchanged	May. 06
Transcript : Demant A/S, Q1 2024 Interim Management Statement Call, May 06, 2024	May. 06
Hearing Healthcare Company Demant Affirms FY24 Outlook	May. 06	MT
Demant A/S Provides Earnings Guidance for the Year 2024	May. 06	CI
Denmark's Demant Finalizes Capital Reduction	Apr. 08	MT
Competition Regulator Clears Cochlear’s Acquisition of Oticon Medical’s Cochlear Implant Business	Apr. 03	MT
Demant Seeks Acquisitions	Mar. 12	CI
Transcript : Demant A/S - Analyst/Investor Day	Mar. 12
Nordic Stocks Closed Down Wednesday; Electrolux Series a Posted Biggest Loss	Feb. 28	DJ
Anja Madsen Announces Not to Stand for Re-Election to the Board of Directors of Demant A/S	Feb. 07	CI
Nordic Shares Rose Tuesday; Demant Climbed Highest	Feb. 06	DJ
DEMANT : In-line Q4; markets cheer the promising takeaways for 2024	Feb. 06
Global markets live: BP, Palantir, Infineon, Toyota, UBS...	Feb. 06
Transcript : Demant A/S, 2023 Earnings Call, Feb 06, 2024	Feb. 06
US Futures Mixed, European Stocks Rise as Investors Parse More Fedspeak	Feb. 06	DJ
Tranche Update on Demant A/S's Equity Buyback Plan announced on March 5, 2021.	Feb. 06	CI
Demant A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 06	CI
Demant Forecasts Up to 8% Organic Revenue Growth in FY24	Feb. 06	MT
Demant to Explore Strategic Options for Communications Business Amid Weak Market Conditions	Feb. 05	MT
Demant A/S Provides Earnings Guidance for the Year 2024	Feb. 05	CI
Demant A/S Promotes Peter Pudselykke as Head of Investor Relations Effective 1 March 2024	Jan. 03	CI
Demant to Recommence Share Buybacks	Nov. 21	MT
Nordic Stocks Dropped Tuesday; Demant Took Biggest Hit	Nov. 07	DJ
DEMANT : Sales broadly in-line; guidance narrowed	Nov. 07
Transcript : Demant A/S, Q3 2023 Interim Management Statement Call, Nov 07, 2023	Nov. 07

Chart Demant A/S

Duration

Period

More charts

Company Profile

Demant A/S is the world's 2nd leading producer of audio products. Net sales (excluding activities held for sale) break down by family of products as follows: - tailor-made hearing aids (44.7%): hearing aid and audiphones sold under the Oticon, Bernafon, Philips and Sonic brands; - hearing care products (40.5%): sold in clinics under the brands Audika, HearingLife, Hidden Hearing and Acústica Médica; - diagnostic products (1116%): audiometers sold under the brands Maico, Interacoustics, amplivox, gsi, MedRx and audioscan; - business communication solutions (3.7%). Net sales (excluding activities held for sale) are distributed geographically as follows: Denmark (1.2%), France (9.9%), Europe (29.7%), the United States (34.1%), North America (7%), Asia (10.4%), Pacific (4.9%) and other (2.8%).

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-21 - Deutsche Bank Conference

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

DEMANT : Q1 sales miss; organic growth guidance unchanged

May 06, 2024 at 11:18 am EDT

More Strategies

Ratings for Demant A/S

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

323.2 DKK

Average target price

332.6 DKK

Spread / Average Target

+2.92%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Prosthetics

	1st Jan change	Capi.
DEMANT A/S	+10.07%	10.2B
STRAUMANN HOLDING AG	-9.51%	21.11B
SONOVA HOLDING AG	+8.42%	18.8B
COCHLEAR LIMITED	+11.12%	14.12B
EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD.	-12.55%	2.22B
EMBLA MEDICAL HF.	+8.56%	1.78B
ANGELALIGN TECHNOLOGY INC.	+34.04%	1.64B
MODERN DENTAL GROUP LIMITED	+24.42%	648M
ANGEL ROBOTICS CO., LTD.	0.00%	394M
DELCATH SYSTEMS, INC.	+78.61%	196M

Medical Prosthetics